Cingulate (CING) Non Operating Investment Income (2022)

Cingulate's (CING) quarterly Non Operating Investment Income came in at $3249.0 in Q3 2022, up 797.21% on a QoQ basis from -$466.0 in Q2 2022.

Cingulate (CING) Non Operating Investment Income (2022) Analysis & Trends

Cingulate (CING) has 1 years of Non Operating Investment Income data on file, last reported at $3249.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Investment Income (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Cingulate	72.85 Mn	72.85 Mn	-	-

Download Data